$29.38−0.78 (−2.59%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Definium Therapeutics (DFTX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+226.3%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼69.1%
−183.8
FY21→FY25CAGR —
Diluted EPS▼33.8%
−2.06
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+226.3%
27.4mn → 89.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6504, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 169,811.0 | 117,665.0 | 65,297.0 | 52,124.0 | 36,169.0 | 34,789.0 | ▲80.2% | +35.6% |
Selling, general & admin | 84,343.0 | 48,644.0 | 38,619.0 | 41,742.0 | 30,162.0 | 59,065.0 | ▲26.0% | −4.7% |
Total operating expenses | 254,154.0 | 166,309.0 | 103,916.0 | 93,866.0 | 66,331.0 | 93,854.0 | ▲60.0% | +15.4% |
Operating incomefeeds ROC rank | −254,154.0 | −166,309.0 | −103,916.0 | −93,866.0 | −66,331.0 | −93,854.0 | ▼60.0% | — |
Other income, net | −83,327.0 | −17,484.0 | −4,763.0 | −1,866.0 | 9,535.0 | −339.0 | — | — |
Pretax income | −337,481.0 | −183,793.0 | −108,679.0 | −95,732.0 | −56,796.0 | −94,193.0 | ▼69.1% | — |
Income tax | — | — | — | — | — | −1,157.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −337,481.0 | −183,793.0 | −108,679.0 | −95,732.0 | −56,796.0 | −93,036.0 | ▼69.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.04 | −2.06 | −1.54 | −2.44 | −1.84 | −3.40 | ▼33.8% | — |
Diluted shares (mn) | 137.35 | 89.33 | 70.46 | 39.16 | 30.86 | 27.38 | ▲26.8% | +34.4% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

